ESMO 2024

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

02:10 PM

Duration 10mins Sevilla Auditorium - Hall 2

Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)

Yopp A, Chen M, Cheng A, Kaseb A, Kudo M, Lee HC, Cha E, Hack S, Lian Q, Spahn J, Wu C, Shukui Q

Oncology | Liver Cancer

06:00 AM

Duration 8hrs Barcelona, Spain

Phase I Study of SOF10 Plus Atezolizumab in Patients with Advanced/Recurrent Solid Tumours

Toshihiko Doi, Yasutoshi Kuboki, Shigehiro Koganemaru, Takafumi Koyama, Jun Sato, Yuki Katsuya, Eisuke Ueda, Kei Higashikawa, Takaaki Ishida, Mikiko Nakamura, Shizuka Nakagawa, Noboru Yamamoto

Solid Tumors | Oncology

07:00 AM

Duration 8hrs Barcelona, Spain

Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study

Dziadziuszko R, Damian S, Gadgeel S, Garralda E, Italiano A, Kim JE, Krzakowsi M, Lin C-C, Popovtzer A, Thomas D, Kirschbrown W, Patel S, Pham T, Sbirnac M, Wu F, Barlesi F

Oncology | Tumor Agnostic Biomarker Positive Cancer

Duration 8hrs Barcelona, Spain

IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 tumour cell (TC) >=50% NSCLC who were disease free at 5 years (5yDF) in a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)

Enriqueta Felip, Eric Vallières, Olexandr Golobordko, Alex Martinez Marti, Caicun Zhou, Achim Rittmeyer, Antonio Chella, Martin Reck, Roman Vereshchako, Wolfgang Schütte, Morihito Okada, Rüdiger Liersch, Encarnação Teixeira, Heather Wakelee, Lisa Bennett, Barbara Gitlitz, Marcus Ballinger, Cindy Zhu, Leonardo Crama

Oncology | Lung Cancer

Duration 8hrs Barcelona, Spain

Updated efficacy and safety of entrectinib▼ in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC

Matthew G. Krebs, Shun Lu, Yun Fan, Yan Yu, Alexander Drilon, Salvatore Siena, Cloris Xue, Denise Bradley, Xichun Hu

Oncology | Lung Cancer

Duration 8hrs Barcelona, Spain

IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

Heather Wakelee, Martin Reck, Enriqueta Felip, Nasser Altorki, Eric Vallieres, Rüdiger Liersch, Satoshi Oizumi, Hiroshi Tanaka, John T. Hamm, Steven McCune, Elizabeth Bennett, Barbara J Gitlitz, Virginia McNally, Silvia Novello, Marcus Ballinger, Wei Zou, Barzin Y. Nabet, Minu K. Srivastava, Caicun Zhou

Oncology | Lung Cancer

10:00 AM

Duration 1hr Barcelona, Spain

Second OS interim analysis from BEAT-SC: A randomized Phase III study of bevacizumab (bev) or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)

Baohui Han, Yuichiro Ohe, Makoto Nishio, Satoshi Watanabe, Xiubao Ren, Shuji Murakami, Nong Yang, Isamu Okamoto, Gaofeng Li, Nobuyuki Katakami, Xianling Liu, Naohiko Hamaguchi, Yuki Nakagawa, Morihiko Hayashi, Toshihiro Nanki, Chunyu Qian, Nobuyuki Yamamoto

Oncology | Lung Cancer

12:45 PM

Duration 90mins Oviedo Auditorium - Hall 3

Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors

Elena Garralda, Manish R. Patel, Tae Won Kim, Adrian Sacher, Martin Forster, Armando Santoro, Jayesh Desai, Luis Paz-Ares, Alejandro Falcon, Maria de Miguel, Samantha Bowyer, Rafal Dziadziuszko, Se Hyun Kim, Sae-Won Han, Matthew G. Krebs, Patricia LoRusso, Rasha Cosman, Julie Chang, Tomi Jun, Wilson H. Miller Jr.

Oncology | Colorectal Cancer - Lung Cancer

06:30 AM

Duration 8hrs Barcelona, Spain

Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC)

Perez Valderrama B, Garcia del Muro X, Merseburger AS, Loriot Y, Choy E, Castellano D, Lopez-Rios F, Bonfill T, Montesa A, Yu P, Skamnioti P, Sternberg CN

Oncology | Urinary Bladder Cancer

07:00 AM

Duration 8hrs Barcelona, Spain

Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study

Bochtler T, Kramer A, Pauli C, Duran-Pacheco G, Arslan C, Bigot F, Chalabi N, Cook N, Italiano A, Losa F, Janoski de Menezes J, Ma N, Ozguroglu M, Pazo-Cid R.A, Ross J.S, Shiu K.K, Arni P, Moch H, Mileshkin L

Oncology | Carcinoma of Unknown Primary

Duration 8hrs Barcelona, Spain

Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry

Le Tourneau C, Dienstmann R, Hackshaw A, Geissler J, Ferro A, Cheese E, Schirghuber E, Blay J-Y

Oncology | Solid Tumors

07:00 AM

Duration 8hrs Barcelona, Spain

Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS Breast Cancer (BC): A Phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)

Oliveira M, Gion M, Jung H, Bermejo M, Hurvitz S, Sadeghi S, Wander S, Seock I, Gal-yam E, Zhu J, Schwab R, Ngo H, Collier A, Cannon M, Cahuzac C, Pablo P, McIntosh S, Saavedra C, Sonnenblick A.

Oncology | Breast Cancer

12:50 PM

Duration 5mins Sevilla Auditorium - Hall 2

ALINA: exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

Solomon BJ, Wu Y-L, Dziadziuszko R, Barlesi F, Nishio M, Ahn J-S, Horinouchi H, Hochmair M, de Marinis F, Migliorino MR, Kurochkin A, Harputluoglu H, Planchard D, Korphaisarn K, Han J-Y, Ochi Lohmann T, Cardona A, Archer V, Nowicka M, Noe J

Oncology | Lung Cancer

12:55 PM

Duration 10mins Madrid Auditorium - Hall 2

Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity

Thorball CW, Quandt Z, Saha A, Yao L, Middha P, Xu Y, Bejan CA, Hodel F, Stravodimou A, Shearer-King ES, Aldrich M, Phillips EJ, Liu G, Schoenfeld A, Johnson DB, Ziv E, Fellay J, Mohindra R, Balko J, Chandler GS

Oncology | Pan-tumor

I am a healthcare professional

Notice

Cookies

External site

ESMO 2024